Kezar Life Sciences President & CSO Kirk resigns, enters $41K/mo advisor deal

Kezar Life Sciences, Inc.

Christopher Kirk resigned as President and CSO effective April 21, 2023, remains on board.
Advisor agreement runs April 22 to Dec 31, 2023 at $41,050/month plus COBRA premiums.
Kirk declines cash and equity compensation under Non-Employee Director Compensation Policy during term.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher Kirk

President and Chief Scientific Officer

KZR · Kezar Life Sciences, Inc.

Effective: 2023-04-21
Filed: April 27, 2023, 7:59 PM ET

On April 21, 2023, as previously announced, Christopher Kirk, Ph.D. resigned from his role as President and Chief Scientific Officer of Kezar Life Sciences, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Kirk resigned as President and Chief Scientific Officer at Kezar Life Sciences, Inc..

Action: resigned
Role: President and Chief Scientific Officer

Exact text from the filing

On April 21, 2023, as previously announced, Christopher Kirk, Ph.D. resigned from his role as President and Chief Scientific Officer of Kezar Life Sciences, Inc. (the “Company”).

View on SEC.gov

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-015303

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.